A Philadelphia Court of Common Pleas judge reduced the jury verdict in *McKivision v. Monsanto* from $2.25 billion to $400 million, granting a post-trial remittitur motion filed by Monsanto and its parent company, Bayer AG [1]. The ruling eliminates roughly $1.85 billion of the original award while leaving a substantial damages judgment intact. The same judge separately rejected Monsanto's motion to remove him from the case, finding the recusal effort was a delay tactic rather than a legitimate challenge to his impartiality [1].
The case sits within a sprawling mass-tort docket centered on allegations that glyphosate, the active herbicide ingredient in Roundup, causes non-Hodgkin lymphoma and that Monsanto failed to warn consumers of that risk [1]. Bayer acquired Monsanto in 2018 and inherited the litigation. As of March 2026, Bayer had resolved approximately 100,000 Roundup claims for roughly $11 billion in settlements, but approximately 61,000 active cases remain pending [1]. Bayer has publicly described the aggregate liability exposure as an existential threat to the company. The McKivision verdict, even as reduced, reflects the scale of individual awards juries continue to return in cases that proceed to trial rather than settle.
Remittitur, the procedural mechanism the court applied here, allows a trial judge to reduce a jury award found to be excessive under governing legal standards, typically as an alternative to granting a new trial on damages. Pennsylvania courts apply a remittitur standard that asks whether the verdict shocks the conscience or bears no reasonable relationship to the evidence of harm. The judge's decision to cut the award by more than 82 percent signals a finding that the original punitive component substantially exceeded that threshold, though the court left a damages figure that still represents a significant individual recovery [1].
The ruling sets up a near-certain appellate record. Either party may challenge the remitted amount, with plaintiffs likely arguing the reduction went too far and Monsanto preserving its broader arguments that federal pesticide law preempts state failure-to-warn claims entirely, a theory the U.S. Supreme Court has not definitively resolved. Meanwhile, the recusal denial forecloses one procedural off-ramp Monsanto pursued, and the case will continue before Judge James Crumlish III [1]. The outcome on appeal, combined with the volume of remaining cases, will bear directly on whether Bayer pursues additional global settlement negotiations or litigates a larger share of the pending docket to verdict.
Comments (0)